- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities appeared first on Oculis.
The post Oculis' Pioneer Program: Optic Neuritis as a Proof of Concept for Retinal Neuroprotection appeared first on Oculis.
The post First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis appeared first on Oculis.
The post Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities appeared first on Oculis.
The post Oculis acquires development and commercial rights to Privosegtor appeared first on Oculis.
The post Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company appeared first on Oculis.
The post Oculis Reports Q2 2026 Financial Results and Provides Company Update appeared first on Oculis.
The post FDA feedback supports new testing path for therapy in MS relapses appeared first on Oculis.
The post Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses appeared first on Oculis.
The post Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities appeared first on Oculis.